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Abstract Evaluating mitogenic signaling specifically
through the human insulin receptor (IR) is relevant for
the preclinical safety assessment of developmental
insulin analogs. It is known that overexpression of IR
sensitizes cells to the mitogenic effects of insulin, but
it is essentially unknown how mitogenic responses
can be optimized to allow practical use of such
recombinant cell lines for preclinical safety testing.
We constitutively overexpressed the short isoform of
the human insulin receptor (hIR-A, exon 11-negative)
in L6 rat skeletal myoblasts. Because the mitogenic
effect of growth factors such as insulin is expected to
act in G0/G1, promoting S-phase entry, we developed
a combined topoinhibition + serum deprivation
strategy to explore the effect of G0/G1 synchroniza-
tion as an independent parameter in the context of
serum deprivation, the latter being routinely used to
reduce background in mitogenicity assays. G0/G1
synchronization significantly improved the mitogenic
responses of L6-hIR cells to insulin, measured by
3H-
thymidine incorporation. Comparison with the paren-
tal L6 cells using phospho-mitogen-activated protein
kinase, phospho-AKT, as well as
3H-thymidine
incorporation end points supported that the majority
of the mitogenic effect of insulin in L6-hIR cells was
mediated by the overexpressed hIR-A. Using the
optimized L6-hIR assay, we found that the X-10
insulin analog was more mitogenic than native human
insulin, supporting that X-10 exhibits increased
mitogenic signaling through the hIR-A. In summary,
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Abbreviations
BSA Bovine serum albumin
EGF Epidermal growth factor
EGFR EGF receptor
hIR Human insulin receptor
hIR-A, IR-A Human insulin receptor, A (exon
11
Minus) isoform
hIR-B, IR-B Human insulin receptor, B (exon
11
Plus) isoform
hIGF-1R Human insulin-like growth factor
receptor
MAPK Mitogen-activated protein kinase
PKB Protein kinase B Akt
pRb Retinoblastoma protein
AspB10 human
insulin
X-10
Introduction
One of the major advances in diabetes therapy over
the last decade has been the development of short-
acting (“prandial”) and long-acting (“basal”) insulin
analogs. Such insulin analogs provide the clinical
ability to better reproduce the pattern of fasting and
mealtime insulin secretion, leading to improved
glycemic control (Eckel 2005; Garg 2005; Kurtzhals
2004; Vajo et al. 2001; Zib and Raskin 2006).
Human insulin has, in addition to the classical
actions on glucose, fat, and protein metabolism, also
less well-explored mitogenic effects. Insulin binds to
and activates the cognate insulin receptor (IR) as well
as, with a 100–1,000-fold lower affinity, the closely
related insulin-like growth factor 1 receptor (IGF-1R).
Furthermore, insulin can activate hybrid receptors
formed by IR and IGF-1R chains. Traditionally, the
IR was thought to mediate metabolic responses, while
the IGF-1R was thought to mediate mitogenic and
antiapoptotic responses (Dupont and LeRoith 2001;
Lammers et al. 1989; Nakae et al. 2001). However, it
is becoming increasingly clear that activation of the IR
by insulin can also cause mitogenic effects (Alexander-
Bridges et al. 1992; Berhanu et al. 1997;C h o ue ta l .
1987;G i o r g i n oe ta l .1991; Hofmann et al. 1989;
Kaburagi et al. 2004; Lammers et al. 1989; Mur et al.
2008; Randazzo et al. 1990; Shymko et al. 1997, 1999;
Urso et al. 2003) and that such mitogenic control by
the IR has physiological relevance (Okada et al. 2007).
In humans, where two IR isoforms exist (hIR-A and
hIR-B), the short isoform (hIR-A) has been described
to be more developed towards mitogenic signaling
than the hIR-B isoform (Sciacca et al. 2003).
In order to develop insulin analogs with improved
pharmacokinetic properties, structural changes are
introduced in native human insulin, which could
potentially change the mitogenic properties of the
molecule. For example, X-10 human insulin is a
quick-acting insulin analog which differs from human
insulin by a single-amino-acid substitution (Schwartz
et al. 1987; Vincent et al. 1995). During preclinical
development, suprapharmacological doses of X-10
caused mammary adenocarcinomas in female
Sprague-Dawley rats, and further development was
therefore discontinued (The European Agency for the
Evaluation of Medicinal Products 2001).
Tumors caused by growth factors such as insulin
are expected to arise by receptor-mediated (non-
genotoxic) mechanisms. Generally, receptor-
mediated carcinogenesis is assumed to involve
binding of growth factors to cognate receptors on
preneoplastic cells, followed by for example mito-
genic, antiapoptotic, vasogenic, or migratory effects,
all promoting cancer progression. These steps in
receptor-mediated carcinogenesis are all very well
suited for modeling in mammalian cell cultures in
vitro, with mitogenesis appearing to have a predictive
value for cancer development (Christov et al. 2007).
In fact, in all mammalian cell culture systems where
this has been examined, X-10 insulin was between
threefold and tenfold more mitogenic than native
human insulin (Berti et al. 1998; Bornfeldt et al.
1991; Hamel et al. 1999; Milazzo et al. 1992; Slieker
et al. 1997; Vajo et al. 2001; Zib and Raskin 2006).
Therefore, determining in vitro mitogenic potency
compared to native human insulin constitutes an
important part of the preclinical safety assessment of
developmental insulin analogs, supplementary to
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Agency for the Evaluation of Medicinal Products
2001).
As mentioned above, insulin and insulin analogs
can interact with several receptors (hIR-A, hIR-B,
hIGF-1R, and hybrids), all of which can potentially
mediate mitogenic signaling. Further complicating
matters, the effects of IR and IGF-1R are expected
to depend on crosstalk with other membrane recep-
tors, particularly the EGFR (Ahmad et al. 2004;
Kreuzer et al. 2004; Ornskov et al. 2006). In the
context of preclinical in vitro mitogenicity safety
evaluation, this can be addressed by using a panel of
different cell lines, allowing evaluation of the mito-
genic effects of the insulin analog on different
receptors and in different cellular backgrounds (Le
2007). Because the increased mitogenic potency of X-
10 insulin has been ascribed to increased occupancy
at the IR (De Meyts et al. 1993, 1994; Hansen et al.
1996; Shymko et al. 1997; Shymko et al. 1999), as
well as increased affinity for the IGF-1R (Kellerer and
Haring 2001; Kurtzhals et al. 2000), cell lines where
the mitogenic effect of insulin is mediated mainly by
the hIR are very relevant for preclinical safety
assessment of new insulin analogs. Yet, while still
not completely resolved, there is convincing evidence
to suggest that IGF-1R has a stronger mitogenic
signaling capability than the IR (Lammers et al. 1989;
Mastick et al. 1994; Nakae et al. 2001; Urso et al.
1999). This could explain why despite the low affinity
of insulin and its analogs for the IGF-1R, in very few
if any nonmodified mammalian cell types naturally
coexpressing IR and IGF-1R, are mitogenic responses
to insulin mediated primarily by the IR (Eckardt et al.
2007; Milazzo et al. 1997; Ohsugi et al. 2005), and
the IGF-1R appears to contribute significantly to the
mitogenic effect of even low nanomolar insulin levels
in cell lines coexpressing IR and IGF-1R (Milazzo et
al. 1997). Therefore, recombinant overexpression of
hIR is used to generate cell lines for preclinical safety
assessment of developmental insulin analogs (Berti et
al. 1998). For preclinical safety assessment, the
mitogenic potency of developmental insulin analogs
is compared to the mitogenic potency of native
human insulin, based on EC50 values determined
from full dose–response curves spanning picomolar to
micromolar insulin concentrations. However, it is
currently unknown how mitogenic responses to
insulin might be improved in recombinant hIR-
overexpressing cell lines. Therefore, we overexpressed
hIR-A in L6 rat skeletal muscle cells and explored the
parameters influencing mitogenic responses to human
insulin in the recombinant cell line.
Materials and methods
Materials
Materials included the following: native human
insulin (S100 reference solution, Novo Nordisk A/
S), Dulbecco’s modified Eagle’s medium (DMEM)
with 5 mM glucose, fetal calf serum (FCS), penicil-
lin–streptomycin–glutamine mix (10,000 U/ml peni-
cillin, 10,000 μg/ml streptomycin, and 29.2 mg/ml
L-glutamine), trypsin–EDTA, phosphate-buffered sa-
line (PBS), and geneticin (50 mg/ml; Gibco). Tissue
culture flasks and 96-well microtiter plates (Nunclon
Surface, Nunc) were used, as well as 6-
3H-thymidine
(Amersham Biosciences), BSA, propidium iodide,
and RNaseI (Sigma).
Cell culture
L6 rat skeletal muscle cells constitutively overex-
pressing the human IR under control of the CMV
promoter were produced by transfection with a
plasmid cDNA clone of the human IR (short isoform,
lacking exon 11), followed by selection in geneticin
and cloning. The resulting cell line, L6-hIR cells,
express approximately 50×10
3 hIR-A per cell. The
hIR isotype in the recombinant cell line was con-
firmed by DNA sequencing.
L6-hIR cells were maintained at 37°C in a 5%
CO2-humidified atmosphere in growth medium:
DMEM, 5 mM glucose, 10 vol.% FCS, 100 U/ml
penicillin, 100 μg/ml streptomycin, 292 μg/ml gluta-
mine, and 1 mg/ml geneticin. To keep cultures in a
proliferative (asynchronous) state, subculturing at a
1:3 split ratio was done every 2–3 days.
Insulin signaling analysis
Exponentially growing L6-hIR and parental L6 rat
skeletal muscle cells were washed with PBS, trypsi-
nized, centrifuged (100×g, 5 min), and resuspended in
growth medium with 10% FCS at 2.5×10
5 cells per
milliliter. The cells were seeded in 12-well plates at
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treated with human insulin or IGF-1 diluted in growth
medium without FCS but containing 0.5% BSA as
carrier. The concentrations of human insulin and IGF-1
covered the range 0.001–1,000 nM. The cells were
incubated for 10 min at 37°C in a 5% CO2-humidified
atmosphere, washed with ice-cold PBS, snap-frozen in
liquid nitrogen, and scraped off the plate in 100-μl
lysis buffer (Cell Extraction Buffer, Bio Source,
Invitrogen). The cell lysates were transferred to cold
Eppendorf tubes, incubated at room temperature for
20 min, and centrifuged (20,000×g, 15 min, 4°C), and
the resulting supernatants were transferred to new cold
Eppendorf tubes. The protein content of the super-
natants was determined with the BCA method (Thermo
Scientific). Western blotting with phosphospecific
antibodies was done as described below. Western blots
were quantitated using the Science Lab 2001 Image-
Gauge version 4 software (Fujifilm, Sweden).
Synchronization of L6-hIR cells by combined
topoinhibition and serum deprivation
Exponentially growing L6-hIR cells were seeded in
growth medium with 10% FCS in six 175-cm
2 culture
flasks, at six different starting densities: flasks 1, 2, 3, 4,
5, and 6 were seeded with 1×10
5,5 × 1 0
5,1×1 0
6, 2.3×
10
6,1 . 2 × 1 0
7,a n d2 . 3 × 1 0
7 cells in total, respectively.
After 48-h incubation, monolayers were washed
with PBS and refed with starvation medium with
0.1% FCS: DMEM, 5 mM glucose, 0.1 vol.% FCS,
100 U/ml penicillin, 100 μg/ml streptomycin, 292 μg/
ml glutamine, and 1 mg/ml geneticin. After 24 h, the
cells were seeded in 96-well plates for insulin
mitogenicity assay as described below.
Insulin mitogenicity assay
L6-hIR cells at varying degrees of synchronization in
T175 flasks numbers 1 through 6, prepared as
described above, were washed with PBS and trypsi-
nized. Cells were centrifuged (100×g, 5 min) and
resuspended in starvation medium with 0.1% FCS at
4×10
5 cells per milliliter.
Cells were seeded in 96-well plates at 100-μl
suspension per well. Following 1-h incubation to
allow cells time to settle, 100 μlp e rw e l lo f
recombinantly produced native human insulin (Novo
Nordisk A/S reference solution) serially diluted in
starvation medium with 0.1% FCS was added. After
18–20-h stimulation with human insulin, 20 μlo f
6.25 μCi/ml
3H-thymidine (Amersham Biosciences)
was added, and the plates were incubated for 2 h.
Scintillation counting of
3H-thymidine incorporated
into cellular DNA was done using a TopCount NXT
scintillation counter (Packard), as recommended by
the manufacturer.
Bivariate flow cytometric analysis of hIR expression
and cell cycle distribution
L6-hIR cells were washed with PBS and trypsinized
briefly to minimize perturbation of surface receptors.
Cells were centrifuged (100×g, 5 min, 4°C) and
resuspended at 2×10
6 cells per milliliter in ice-cold
growth medium with 10% FCS, supplemented with
0.1% sodium azide.
Cells were incubated with 5 µg/ml murine mono-
clonal antibody 83-7 against hIR for 1 h on ice (Soos
et al. 1986), followed by washing and incubation for
1hd a r ko ni c ew i t hf l u o r e s c e i ni s o t h i o c y a n a t e
(FITC)-conjugated goat antimouse F(ab′)2 fragment
(DAKO F0479). Negative controls included samples
without any antibody added, samples added 5 μg/ml
isotype control IgG1 murine monoclonal antibody
and FITC-conjugated secondary antibody, and sam-
ples added only FITC-conjugated secondary antibody.
Following incubation with antibodies, cells were
washed, resuspended gently but completely in 200 µL
PBS, 1% FCS, and 0.1% sodium azide, and fixed by
adding 2 ml 70% ethanol, followed by immediate
vortexing. The fixed cells were washed with PBS, 1%
FCS, and 0.1% sodium azide and resuspended in
50 μg/ml propidium iodide, 2 mg/ml RNAseI, 1.12%
citrate, pH 7.4. Double-stained suspensions were
analyzed using a FACSCalibur flow cytometer
(Becton Dickinson). Width versus area propidium
iodide fluorescence pulse plots (F3W/A plots) were
used to exclude cell doublets and aggregates. DNA
content and cell cycle position was determined in the
F3 channel, and FITC fluorescence (hIR expression)
was determined in the F1 channel. Analysis was done
with CellQuest Pro software
Immunofluorescent analysis of hIR expression
For immunofluorescent analysis (IFA), L6-hIR cells
were seeded on glass chamber slides and allowed to
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nalization, all staining steps were done at 4°C, using
ice-cold growth medium supplemented with 0.1%
sodium azide for washes and antibody dilutions.
Monolayers were incubated with 1 µg/ml of
murine monoclonal antibody 83-7 (IgG1; Soos et al.
1986), diluted in growth medium supplemented with
0.1% sodium azide, for 1 h at 4°C. For negative
control, a murine antiserotonin monoclonal antibody
was used (clone 5HT-H209, IgG1 kappa, DAKO,
M0758).
Following washing, the monolayers were incubat-
ed with FITC-conjugated, affinity-isolated goat anti-
mouse F(ab′)2 fragment (DAKO F0479) for 1 h at
4°C. Following postfixation in 1% paraformaldehyde,
counterstain of nuclei with 1 µg/ml 4′,6-diamidino-2-
phenylindole (DAPI), and mounting in antifade
medium, monolayers were examined by fluorescence
microscopy.
Fully denaturing and reducing Western blotting
Unless otherwise stated, subconfluent cell monolayers
were directly lysed in sample buffer (LDS buffer,
Invitrogen). Sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and electrotransfer to polyvinyli-
dene fluoride membranes were done using the
NuPage utensil and reagent suite (Invitrogen).
Filters were probed with primary and secondary
antibodies and visualized with chemiluminescent
substrate (ECL
Advance, GE Healthcare) using a CCD
camera (LAS3000, FujiFilm) as recommended by the
manufacturers.
The following primary antibodies were used:
antihuman/rat/mouse phospho-retinoblastoma protein
rabbit immunoglobulin (Ser807/811, Cell Signaling,
#9308), antihuman/rat/mouse caspase 3 rabbit immu-
noglobulin (Cell Signaling #9662), phospho-Akt
(Ser473) antibody (Cell Signaling #9271), and anti-
ACTIVE® mitogen-activated protein kinase (MAPK)
pAb (Promega, V8031). To verify equal protein
loading, we used a cocktail of murine monoclonal
antibodies to alpha-tubulin (T6199), GAPDH
(ab8245), and beta-actin (ab6276) from Sigma and
Abcam.
Secondary antibodies (horse-radish-peroxidase-
conjugated rabbit antimouse immunoglobulin and
horse antirabbit immunoglobulin) were from Cell
Signaling.
Results
Characterization of IR expression and insulin
signaling in L6-hIR and parental L6 rat skeletal
muscle cells
Expression of the human IR on the surface of stably
transfected rat L6 cells was confirmed by immuno-
fluorescence, using monoclonal antibody 83-7,
which recognizes human but not rat IR (Soos et al.
1986;F i g .1a). The expression of high levels of IR
was confirmed by Western blotting, comparing the IR
expression in L6-hIR cells with the parental L6 cells
(data not shown). Western blotting also demonstrated
that both the L6-hIR and L6 cells expressed very low
comparable levels of the rat IGF-1R (data not shown).
Both MAPK and protein kinase B Akt (PKB) have
been described to be involved in mitogenic responses
to insulin and IGF-1. Based on phosphorylation of
MAPK, L6-hIR cells were 355-fold more sensitive
than the parental L6 cells to the effect of insulin
(Fig. 1b). Based on phosphorylation of PKB, L6-hIR
cells were 275-fold more sensitive than the parental
L6 cells to the effect of insulin (Fig. 1c), i.e., both
MAPK and PKB end points gave essentially the same
estimate of the degree to which L6-hIR cells were
sensitized to insulin. By contrast, the EC50 values of
IGF-1 were comparable between the two cell systems
(Fig. 1b, c). This strongly suggested that the increased
sensitivity of L6-hIR cells to the effect of insulin was
due to the overexpression of the human IR-A.
Graded G0/G1 synchronization of L6-hIR cells
independent of serum deprivation
Serum deprivation is routinely used for in vitro
mitogenicity assays to reduce background prolifera-
tion levels and thus increase sensitivity. To explore
the specific effect of G0/G1 synchronization in the
context of serum deprivation, we exploited the fact
that L6-hIR cells readily arrested in G0/G1 in
response to topoinhibition, i.e., under conditions of
high confluence. Thus, to coordinately generate
L6-hIR cultures at different levels of synchronization,
six parallel flasks seeded at different densities were
incubated for 2 days in growth medium (with 10%
FCS), allowing topoinhibition to occur in some flasks.
Then, all flasks were incubated for 1 day in medium
with 0.1% serum. This strategy generated six parallel
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“flask 6,” spanning cell densities from subconfluent in
flasks 1 and 2 confluent in flasks 3 and 4 to highly
confluent with many detached cells in flasks 5 and 6.
In flasks 1 through 3, increasing levels of G0/G1
cells and decreasing levels of S-phase and G2/M-
phase cells were present (Fig. 2a). The proliferating
fraction, defined as cells in S and G2/M, was strongly
and significantly reduced from flask 1 to flask 3 and
remained at low and comparable levels in flasks 3
through 6. Levels of pRb, a marker for S-phase entry,
decreased from flask 3 to 4 (Fig. 2b). Thus, the
combined flow cytometric cell cycle and Western blot
data showed that, by using topoinhibition, G0/G1
Fig. 1 Characterization of IR expression and insulin-mediated
signaling in L6-hIR cells. a Confirmation of hIR expression on
the surface of L6-hIR cells: live, exponentially growing L6-hIR
monolayers on glass slides were stained with mAb 83-7, which
recognizes a conformational epitope of human but not rat IR
(Soos et al. 1986; left double panel) or an antiserotonin mAb as
negative isotype control (right double panel). Following
postfixation with paraformaldehyde, nuclei were counterstained
with DAPI. b, c Stimulation of phosphorylation of MAPK (b)
and PKB (c) by human insulin and IGF-1 in L6-hIR and L6
cells. Concentrations of human insulin, X-10, and IGF-1 are
shown in nanomolar on a logarithmic scale, i.e., 0 indicates
1 nM, 1 indicates 10 nM, −1 indicates 0.1 nM, etc. Data points
represent means of triplicate Western blots; error bars show ±1
standard deviation
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serum deprivation (Fig. 2a, b).
In flasks 4 through 6, the G0/G1 percentages were
comparable, but S-phase percentages appeared to
increase (Fig. 2a). The S-phase data for flasks 4
through 6 were variable, likely reflecting a beginning
degeneration of the monolayers. Perhaps for this
reason, levels of pRb were not increased in flasks 4
through 6 (Fig. 2b).
A gradual increase in apoptosis was observed in
flasks 3 through 6, by Western blotting for caspase 3
(Fig. 2c). Thus, it is possible that the slightly
Fig. 2 Topoinhibition allows graded G0/G1 synchronization of
L6-hIR cells. a G0/G1 synchronization of L6-hIR cells: different
levels of topoinhibition across six tissue culture flasks with
L6-hIR cells were accomplished as described in “Materials and
methods.”“ Flask number 1” corresponded to low-confluence
cells and “flask 6” to overconfluent cells with beginning
degeneration of the monolayer. From flasks 1 through 6, L6-hIR
monolayers were trypsinized; cell suspensions were fixed with
ethanol and stained with propidium iodide and analyzed by flow
cytometry. Cell cycle distributions were determined by mathe-
matical modeling of DNA histograms with ModFit software
(Verity Software House). Values are means from five independent
experiments; error bars represent one standard deviation. Apo-
ptotic (sub-G0/G1) fractions were observed in increasing amounts
through flasks 1–6 and were excluded from analysis, i.e., in all
cases, percentages of G0/G1,S ,a n dG 2/M cells add up to 100%.
Proliferative fractions were determined based on the data in the
bar diagram, as (S + G2M)/(G0G1), mean of five independent
experiments, ±1 SD. Asterisks, the reduced proliferative fraction
in flask 3, compared to flask 1, was highly statistically significant
(P=0.00146, two-tailed t test). b, c Detection of phospho-
retinoblastoma protein and activated caspase-3: monolayers of
L6-hIR cells in flasks 1 through 6 were lysed in situ. The Western
blots were probed with antibodies against phospho-retinoblastoma
protein (b)o rc a s p a s e3( c). The 17- and 19-kDa bands represent
cleaved (activated) caspase 3. To verify equal protein loading,
blots were probed with a cocktail of three murine monoclonal
antibodies against alpha-tubulin, GAPDH, and beta-actin. Lanes
1–6 correspond to flasks 1–6, respectively (low- through high-
confluency L6-hIR monolayers)
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represented reduced topoinhibition effect due to loss
of adherent cells by apoptosis.
Correlation between G0/G1 synchronization
and mitogenic response to human insulin in L6-hIR cells
L6-hIR cells at six different degrees of synchronization
were used for six parallel insulin mitogenicity assays, as
described in “Materials and methods.” A mitogenic
response to human insulin was observed in L6-hIR
cells regardless of level of synchronization (Fig. 3a).
However, cells at a low degree of synchronization
exhibited flat dose–response curves, with maximal fold
responses around fourfold (Fig. 3a, “flask 1”)w h e r e a s
cells at a higher degree of synchronization responded
with a maximum response above eightfold. Further-
more, G0/G1 synchronization increased the steepness
of the dose–response curves (Fig. 3a, compare for
example “flask 1” and “flask 3”) as well as the maximal
fold response to 100 nM insulin (Fig. 3b). Maximal
fold responses were increased from flasks 1 to 3 and
were reduced from flasks 3 to 6 (P=0.0187, one-way
analysis of variance (ANOVA)). Thus, a clear correla-
tion was observed between the degree of topoinhibition
of cells used for the mitogenicity assay and maximal
fold responses in the mitogenicity assay (Fig. 3a, b).
The mitogenic response to human insulin in L6-hIR
cells is mainly mediated through the hIR, activated
at subnanomolar insulin concentrations,
and associated with high fold responses
L6-hIR and the parental L6 cells were synchronized
in G0/G1 under optimal conditions as described in
“Materials and methods” for flask 3 and exposed to
tenfold dilution series of human insulin, IGF-1, and
X-10 (Fig. 3c, d).
For human insulin, potency was increased 48-fold in
L6-hIR cells (Fig. 3c, d,c o m p a r eE C 50 values for
human insulin in c and d). In contrast, the potency of
IGF-1 was decreased by sixfold in L6-hIR cells
(Fig. 3c, d,c o m p a r eE C 50 values for IGF-1 in L6-hIR
and parental L6 cells). These findings paralleled the
high (human) IR expression in L6-hIR cells (Fig. 1a),
the comparable (rat) IGF-1R expression between
L6-hIR cells and the parental L6 cell line (data not
shown), and the increased sensitivity to human insulin-
mediated signaling (Fig. 1b, c). The slight decrease in
IGF-1 potency in L6-hIR cells could be due to titration
of (rat) IGF-1R into rat/human IR/IGF-1R hybrids or
titration of intracellular signaling molecules by the
overexpressed hIR-A. In any case, these data indicated
that the increased mitogenic response in L6-hIR cells
was specific for the cognate receptor ligand (insulin)
and also that thegreat majority (approximately 1−1/48=
98%)ofthemitogenicresponsetoinsulininL6-hIRcells
was mediated by the hIR-A. Interestingly, X-10 insulin
was more mitogenic than native human insulin in
L6-hIR cells (Fig. 3c), in agreement with IR binding
characteristics being relevant for the well-known
increased mitogenicity of this analog (De Meyts et al.
1993;H a n s e ne ta l .1996;S h y m k oe ta l .1997, 1999).
Reduced hIR-A expression levels correlate
with a reduced mitogenic response to human insulin
in strongly topoinhibited L6-hIR cells
In flasks 3 through 6, apoptosis was observed at the
culture level (Fig. 2c). To examine whether non-
apoptotic cells were also affected by exaggerated
Fig. 3 The mitogenic response of L6-hIR cells to insulin is
improved by G0/G1 synchronization and mediated mainly by
the IR-A: a Mitogenic responses (
3H-thymidine incorporation)
of L6-hIR cultures at different levels of G0/G1 synchronization.
Concentrations of human insulin, X-10, and IGF-1 are shown
in nanomolar on a logarithmic scale, i.e., 0 indicates 1 nM, 1
indicates 10 nM, −1 indicates 0.1 nM, etc. The study was
repeated on four independent occasions, and results from a
typical experiment are shown. b Correlation between mitogenic
responses and G0/G1 synchronization in L6-hIR cells. Four
independent experiments were carried out. Each experiment
comprised graded G0/G1 synchronization of L6-hIR cells in six
flasks, which were used for six parallel mitogenicity experi-
ments using native human insulin as mitogen. Levels of G0/G1
cells, from Fig. 2a are shown on the x-axis. Normalized
mitogenic response values, expressed as maximal fold mitogenic
response compared to flask 1 (serum-deprived but essentially
asynchronous conditions), are shown on the y-axis. Data points
represent mean and SD from four independent experiments. c, d
Mitogenic response to human insulin in L6-hIR cells is mediated
mainly by the human insulin receptor. L6-hIR cells (c)a n d
parental L6 cells (d) were synchronized in G0/G1 under optimal
conditions (flask 3 conditions) and seeded in starvation medium
in 96-wells plates for mitogenicity assays, as described in
“Materials and methods.” Cells were exposed to human insulin,
human IGF-1, and X-10 human insulin for 18 h, and mitogenic
effects were measured by a 2-h pulse label with
3H-thymidine.
Data points represent means of triplicate wells. Concentrations of
human insulin, X-10, and IGF-1 are shown in nanomolar on a
logarithmic scale, i.e., 0 indicates 1 nM, 1 indicates 10 nM, −1
indicates 0.1 nM, etc. Error bars,o n eS D .I nt h ep a r e n t a lL 6
cells, the response curves for insulin and IGF-1 overlap
b
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topoinhibited L6-hIR cells for hIR-A surface expression
and nuclear DNA content, followed by flow cytometric
analysis (Fig. 4a). Apoptotic cells, defined as cells with
sub-G0/G1 DNA content, were excluded from the
analysis. Interestingly, surface hIR expression in non-
apoptotic L6-hIR cells was reduced in flasks 4 through
6. Thus, cellular stress affecting surface expression of
hIR likely explained the strongly reduced mitogenic
responses in flasks 4 through 6 (Fig. 4a).
hIR-A expression positively correlates
with proliferation in the absence of exogenously
added insulin
In the flow experiment described above to examine
surface hIR expression in flasks 2 through 6 (Fig. 4a),
following immunolabeling for surface hIR, cells were
ethanol-fixed and stained with propidium iodide, as
described in “Materials and methods.” This allowed
bivariate flow analysis of surface hIR expression and
cell cycle position at the single-cell level (Fig. 4b).
Paralleling the previously observed synchronization
in G0/G1 (Fig. 2a), proliferative fractions were
reduced from flasks 2 through 4 for hIR
Pos as well
as hIR
Neg cells. For example, for hIR
Pos cells,
proliferative fractions were reduced from 32% to
20% from flask 2 to 6 (Fig. 4b, left panels), and for
hIR
Neg cells, proliferative fractions were reduced from
16% to 9% from flasks 2 to 6 (Fig. 4b, right panels).
However, intriguingly, we found that irrespective of
topoinhibition levels, cells positive for surface hIR
expression exhibited twofold higher proliferating
fractions than did cells negative for surface hIR
expression (Fig. 4b, P<0.0001). The overrepresenta-
tion of proliferating cells in the hIR
Pos fraction was
also observed, albeit less pronounced, in asynchro-
nous L6-hIR cells under exponential growth in
medium with 10% FCS (Fig. 4b, bottom panels).
Discussion
Insulin is thought to exert mitogenic effect by
promoting cell growth in the G0/G1 phase of the cell
cycle, thus facilitating S-phase entry (Derenzini et al.
2005; Goberdhan and Wilson 2003; Kimura et al.
2001; Reid and Reid 1987; Roche et al. 1998; Straus
1984). Thus, cell cultures synchronized in G0/G1
would be expected to be most sensitive to the
mitogenic effect of insulin, but this has never been
directly explored. To specifically examine the effect
of G0/G1 arrest, we generated L6-hIR monolayers
that were all serum-starved to the same extent but
nevertheless contained different levels of G0/G1 cells.
We found that L6-hIR cells that were serum-deprived
but not topoinhibited exhibited cell cycle distributions
essentially identical to proliferating cultures in
medium with 10% FCS (Fig. 2a, flask 1). Such
serum-deprived but not G0/G1-synchronized L6-hIR
cultures exhibited relatively weak mitogenic
responses to human insulin, with EC50 values in the
1–10-nM range (Fig. 3a). With increasing levels of
G0/G1 synchronization, the maximal mitogenic
responses increased significantly (Fig. 3a, compare
flasks 1 through 3), with a significant dose–response
relationship between G0/G1 synchronization levels
and maximal mitogenic responses (Fig. 3a, b, flasks 1
through 3). Excepting “oversynchronized” cultures
where degeneration of the monolayers occurred,
Fig. 4 Surface expression of hIR-A positively correlates with
proliferation under growth-limiting as well as exponential
proliferation conditions in L6-hIR cells: L6-hIR cultures
differing inG0/G1 synchronization levels were produced by
topoinhibition, as in Fig. 3c. Flask 1 (low-confluency cells) did
not provide sufficient cells for flow cytometry. Serum-starved
and topoinhibited L6-hIR cells from flasks 2–6, as well as an
asynchronous populations of L6-hIR and parental L6 cells
(exponentially proliferating, in medium with 10% FCS), were
stained with the anti-IR antibody 83-7 (left panel) or mouse
IgG1 isotype control (right panel) and FITC-conjugated
secondary antibody. Following immunolabeling for surface
hIR, cells were ethanol-fixed and stained with propidium
iodide, allowing bivariate flow analysis of surface hIR expression
and cell cycle position at the single-cell level. Apoptotic cells
(defined as cells with <G0/G1 DNA content) were excluded from
analysis. a hIR expression is reduced in strongly confluent
L6-hIR monolayers. Percentages of cells positive for surface hIR
expression are given in each plot. The histogram marker was set
identically in all plots. b hIR-A expression correlates with a
higher proliferative fraction in L6-hIR cells. Cells exhibiting
surface expression of the human IR-A (hIR
Pos cells) were defined
by the histogram marker shown in a. Cells without surface
expression of the human IR-A (hIR
Neg) cells were defined as
NOT hIR
Pos cells. Cell cycle distributions are shown for gated
hIR
Pos and hIR
Neg cells in the same flask (left and right panels,
respectively). The histogram marker indicates the percentage of S
and G2/M-phase cells, i.e., the proliferative fraction. The
proliferative S + G2/M fraction was on average 2.02-fold higher
in hIR
Pos than in hIR
Neg cells, across flasks 2–6( n=5, SD=0.08,
P<0.0001, one sample t test). Flask number as well as hIR
expression significantly affected cell cycle distributions (two-way
ANOVA, P=0.0360 for flasks, P=0.0006 for hIR expression)
b
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hIR-A expression (Fig. 4a, compare flasks 2 and 3
and asynchronous L6-hIR cells). Thus, our data
unequivocally showed that cells synchronized in G0/
G1 became more sensitive to the mitogenic effects of
human insulin. This finding might explain the modest
insulin mitogenicity response seen in some systems
(Bahr et al. 1997; Berti et al. 1998; Liefvendahl et al.
2008; Staiger et al. 2007)
The mitogenic response of L6-hIR cells to insulin
w a sm e d i a t e dm a i n l yb yt h eh I R - A .T h i sw a s
demonstrated first by comparing the parental L6 cells
with the L6-hIR cells, with the latter being 48-fold
more sensitive to the mitogenic effects of insulin
(Fig. 3a, compare insulin EC50 values in L6-hIR cells
with parental L6 cells). This finding paralleled the
increased sensitivity of the L6-hIR cells to human
insulin-mediated signaling (Fig. 1b, c). Also, our data
Cell Biol Toxicol (2010) 26:293–307 303correspond well with the literature, where 10–100-fold
increases in the mitogenic potency of insulin were
observed in NIH3T3 and Chinese hamster ovary
(CHO) cells following overexpression of hIR-A or
hIR-B (Chou et al. 1987; Hofmann et al. 1989).
Second, the drop in mitogenic response that was
observed with too severe topoinhibition of L6-hIR
cells (Fig. 3a, flask 3–6) correlated with a reduced
hIR-A expression on the surface of nonapoptotic cells
in the cultures (Fig. 4a, compare percentage of hIR-A-
expressing cells in flasks 3 through 6. Apoptotic cells,
defined by sub-G0/G1 DNA content, were excluded
from the analysis). Third, in L6-hIR cells, human
insulin exhibited a 275-fold stronger mitogenic effect
than did IGF-1 (Fig. 3c). This ranking of mitogenic
potencies of insulin and IGF-1 is characteristic of
recombinant cells overexpressing hIR (Hofmann et al.
1989), and the opposite of what is seen in most
mammalian cells, where IGF-1 is at least as strong or
stronger mitogen than insulin.
In contrast to the 48-fold increased mitogenic
potency of insulin in the L6-hIR cells compared to
the parental L6 cells, the mitogenic potency of IGF-1
was reduced by fivefold in L6-hIR cells compared to
parental L6 cells (Fig. 3c, d, compare IGF-1 EC50
values in L6-hIR cells with parental L6 cells). This
suggested that hIR-A overexpression inhibited signal-
ing by the rat IGF-1R. The reduced potency of IGF-1
in L6-hIR cells could be due to recruitment of
endogenous (rat) IGF-1R in hybrid receptors or
titration of intracellular signaling partners by the
overexpressed hIR-A.
Interestingly, in L6-hIR cells, the mitogenic poten-
cy of X-10 insulin was still higher than the mitogenic
potency of native human insulin (Fig. 3c). Because
the mitogenic response in L6-hIR cells was mainly
hIR-driven, this is in accordance with the enhanced
IR binding of X-10 being relevant for the mitogenic
effect of this analog (De Meyts et al. 1993; Hansen et
al. 1996; Kellerer and Haring 2001; Kurtzhals et al.
2000; Shymko et al. 1997, 1999). Importantly, this
does not contradict that the increased mitogenic effect
of X-10 is mediated by IGF-1R in some systems (De
Meyts et al. 1993; Hansen et al. 1996; Kellerer and
Haring 2001; Kurtzhals et al. 2000; Shymko et al.
1997, 1999). Rather, the combined data suggest that
the enhanced IR as well as IGF-1R binding effects of
X-10 may both be relevant to the mitogenic effect of
the analog, depending on cellular context in which in
vitro mitogenicity assays are performed (De Meyts et
al. 1993; Hansen et al. 1996; Kellerer and Haring
2001; Kurtzhals et al. 2000; Shymko et al. 1997,
1999).
Surprisingly, in L6-hIR cells that had been serum-
starved for 24 h and without exogenously added
insulin, cells with surface hIR-A expression were
twofold more likely to be cycling (in S or G2/M) than
cells without hIR-A expression (Fig. 4b). This
positive correlation between hIR-A surface expression
and cycling fraction was maintained in cultures with
increasing levels of confluency (Fig. 4b, flasks 2
through 6). Thus, there was a positive correlation
between hIR-A surface expression and cycling in
L6-hIR cultures under serum-deprived and confluent
conditions, in the absence of exogenously added
insulin (Fig. 4b). At least two explanations could
account for this: first, it is possible that L6-hIR cells
secreted paracrine factors able to activate hIR-A, such
as IGF-II. Second, overexpression of hIR-A might
allow for some ligand-independent activity. Here, it
should be mentioned that, at 50,000 per cell, hIR-A
overexpression in the L6-hIR cells is moderate,
fivefold to 15-fold lower than what was reported
from NIH3T3 cells (Lammers et al. 1989; Riedel et al.
1989), and fourfold higher than what was reported
from CHO cells (Chou et al. 1987). Importantly, with
increased stringency of topoinhibition, apoptosis was
induced in the L6-hIR cells (Fig. 2c). However,
apoptotic cells (defined as cells with below G0/G1
DNA content) were excluded from the analysis in
Fig. 4a, b. Also, the correlation between hIR-A
expression and cycling was also observed in flask 2,
where apoptosis was not detected (Fig. 4b), and the
correlation between hIR-A expression and cycling
was constant in flasks 2 through 6, despite increasing
levels of apoptosis. The correlation between hIR-A
expression and cycling was therefore independent of
apoptosis levels in the L6-hIR cultures (Fig. 4b).
As the G0/G1 synchronization can be accom-
plished by topoinhibition, it might be considered
whether in vitro mitogenicity assays should be
performed under serum-free conditions or with serum
present. In fact, it has in some cases been argued that
“serum starvation does not represent a condition that
occurs physiologically to cancer cells in vivo” (Erbel
et al. 2008). However, while serum is used in cell
culture media at typically 5–10% for its high content
of growth factors, cells in vivo are normally exposed
304 Cell Biol Toxicol (2010) 26:293–307to plasma where clotting-associated growth factors are
not present in high levels, i.e., it could be argued that
having serum in cell culture media represents an
artifactual situation compared to the in vivo situation.
In our experience, serum starvation is generally likely
to reduce background proliferation levels in in vitro
mitogenicity assays and is likely to improve the
sensitivity of in vitro mitogenicity assays. Also, by
performing mitogenicity assays under serum-free
conditions, interactions between the compound under
examination and serum growth factors are minimized.
We therefore believe that in vitro mitogenicity assays
should generally be performed under completely or
essentially serum-free conditions.
In summary, we found that synchronization in G0/
G1 significantly improved the sensitivity of L6 cells
overexpressing the A isoform of the human insulin
receptor to the mitogenic effect of insulin. Our data
strongly support that the mitogenic effect of insulin in
the L6-hIR cell line is mediated mainly by the human
insulin receptor. Under optimal synchronization con-
ditions, the combination of sensitivity and fold
responses of the L6-hIR mitogenicity assay com-
pared very favorably to the most sensitive insulin
in vitro mitogenicity cell systems described, natu-
ral (Allegra and Lippman 1978; Koontz and
Iwahashi 1981; Liefvendahl et al. 2008; Osborne et
al. 1976) as well as recombinant (Chou et al. 1987;
Lammers et al. 1989;R i e d e le ta l .1989). Because it
is known from a number of cell systems and for
many growth factors that mitogenic effects are
exerted in G0/G1, we believe that the findings in
our study may be generally applicable to developing
optimized in vitro mitogenicity assays for growth
factor biopharmaceuticals.
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